Future directions with angiogenesis inhibitors in colorectal cancer

Area of Science:

• Oncology
• Pharmacology
• Medical Imaging

Background:

• Recent US FDA approval of bevacizumab revitalized antiangiogenic research, particularly for colorectal cancer.
• Bevacizumab's success highlights the need for advanced study designs and imaging techniques in antiangiogenic drug development.
• Other promising agents include vatalanib and cyclooxygenase-2 inhibitors, underscoring the importance of these adaptations.

Purpose of the Study:

• To review the impact of bevacizumab approval on antiangiogenic research.
• To discuss the necessity of new study designs and imaging techniques for assessing antiangiogenic drug activity and dose selection.
• To emphasize the importance of understanding response determinants and mechanisms of action for future drug development.

Main Methods:

• Review of current literature on antiangiogenic agents in cancer therapy.
• Analysis of the role of novel study designs and imaging modalities.
• Discussion of the implications of bevacizumab's success and other drug candidates.

Main Results:

• Bevacizumab's approval has spurred significant advancements in antiangiogenic research.
• Adaptations in study design and imaging are crucial for evaluating drug efficacy and determining optimal doses.
• Vatalanib and COX-2 inhibitors show promise, reinforcing the need for these methodological advancements.

Conclusions:

• Understanding the factors influencing response to antiangiogenic agents is critical.
• Further research into the mechanisms of action, especially in combination therapies, is essential for future drug development.
• Continued innovation in study design and imaging will accelerate the progress of antiangiogenic therapies.